畢業(yè)于中山大學(xué)，浙江省腫瘤醫(yī)院放射治療科主治醫(yī)師。 主持浙江省醫(yī)藥衛(wèi)生科技平臺項(xiàng)目靶向Ⅱ型組織型谷氨酰胺轉(zhuǎn)氨酶(TG2)誘導(dǎo)喉癌放射增敏及其機(jī)制研究（2017RC016），主持浙江省腫瘤醫(yī)院優(yōu)才基金項(xiàng)目TG2控制劑KCC009對喉癌Hep-2細(xì)胞放射增敏作用的實(shí)驗(yàn)研究（2012YC003），以第二負(fù)責(zé)人身份參與自然科學(xué)基金面上項(xiàng)目TG2控制劑KCC009增強(qiáng)喉癌細(xì)胞放射敏感性的作用機(jī)制研究（81372437），浙江省自然科學(xué)基金一般項(xiàng)目鼻咽癌患者放射性顳頜關(guān)節(jié)損傷的動態(tài)影像和血清標(biāo)志物研究（Y16H160124），CSCO-默克雪蘭諾腫瘤研究基金（SCORE）項(xiàng)目NRF2抗氧化通路介導(dǎo)鼻咽癌順鉑和耐藥的作用機(jī)理研究（Y-MT2015-005）。 近年來發(fā)表論文共11篇：1 PEI-JING LI WEI-HAN HU TING JIN*.Management of the N0 neck in recurrent laryngeal squamous cell carcinoma.mol clin onc 4: 70-76, 2016 2 TING JIN#, XIAO-ZHONG CHEN# and JIAN-JIANG LIU*, Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma, ONCOLOGY LETTERS, 2015, 10: 1123-1130. 3 Jin T, Zhu Y, Luo JL, Zhou N, Li DC, Ju HX, Fan YT, Liu Y, Zhu YP, Feng HY, Liu LY*, Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer, Int J Colorectal Dis, 2015, 30(3):337-45. 4 Jin T#, Li B#, Chen XZ*, Phase II Trial of Endostar Combined With Gemcitabine and Cisplatin Chemotherapy in Patients With MetastaticNasopharyngeal Carcinoma (NCT01612286), Oncol Res, 2013, 21(6):317-23. 5 Jin T, Lin H, Lin HX, Cai XY, Wang HZ, Hu WH, Guo LB, Zhao JZ*, Treatment and prognosis of patients with recurrent laryngeal carcinoma: a retrospective study, Head Neck Oncol, 2013, 5(2):10. 6 Jin T, Management of the clinically negative neck (N0) of T2N0M0 supraglottic laryngeal carcinoma: A retrospective study, Head Neck Oncol, 2012, 23;4(4):79. 7 Jin T#, Lin HX#, Lin H#, Guo LB#, Ge N, Cai XY, Sun R, Chen WK, Li QL, Hu WH*, Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: a retrospective study, J Transl Med, 2012, 30;10:64. 8 Jin T, Hu WH*, Guo LB, Chen WK, Li QL, Lin H, Cai XY, Ge N, Sun R, Bu SY, Zhang X, Qiu MY, Zhang W, Luo S, Zhou YX, Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma, Chin J Cancer, 2011,30(7):482-9. 9 金廳，胡偉漢，陳曉鐘*，組織型谷氨酰胺轉(zhuǎn)氨酶介導(dǎo)的腫瘤細(xì)胞化療耐藥的研究進(jìn)展，腫瘤研究與臨床，2013，25 (9): 643-645. 10 金廳，胡偉漢*，林輝，適形調(diào)強(qiáng)放射治療誘發(fā)第二原發(fā)癌一例，腫瘤研究與臨床,2012,24(2):143-144 11 金廳，王芳，胡偉漢*，HIF-1α與VEGF在下咽鱗癌中的表達(dá)及其臨床意義.中華放射腫瘤學(xué)雜志,2011,20(5):385-389。